Form 4: Enliven Therapeutics CSO Sells Shares Under 10b5-1 Plan

Enliven Therapeutics' Chief Scientific Officer, Joseph P Lyssikatos, sold 1,500 shares of common stock for $20.03 per share under a pre-arranged trading plan.

Summary

• Joseph P Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, Inc. (ELVN), reported a sale of common stock.
• The transaction involved the disposition of 1,500 shares of common stock.
• The shares were sold at a price of $20.03 per share.
• The sale occurred on September 23, 2025.
• This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2024.
• Following this transaction, Mr. Lyssikatos beneficially owns 931,688 shares of common stock.
• The remaining shares are held indirectly by The Lyssikatos Revocable Trust 12/15/2011, for which Mr. Lyssikatos serves as trustee.

Sentiment

Score: 5

Explanation: The transaction is a pre-scheduled sale under a Rule 10b5-1 plan, which typically indicates a planned liquidity event rather than a change in management's outlook on the company's prospects. The relatively small number of shares sold compared to total holdings also suggests it is not a significant bearish signal.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing reports a routine insider transaction and does not provide information relevant to broader industry trends or competitor analysis.

Related Party Transactions

• The remaining 931,688 beneficially owned shares are held indirectly by The Lyssikatos Revocable Trust 12/15/2011, for which the Reporting Person serves as trustee.

Stakeholder Impact

• The sale of 1,500 shares by the Chief Scientific Officer is a routine, pre-planned transaction and is unlikely to have a significant direct impact on shareholders, employees, customers, suppliers, or creditors.

Key Dates

Recommendation

This Form 4 reports a routine, pre-scheduled insider sale under a 10b5-1 plan. Such transactions are generally not indicative of a change in the company's fundamental outlook or a signal for investors to buy or sell based solely on this filing. Investors should consider broader company performance and market conditions.

Keywords

Enliven Therapeutics, ELVN, Joseph P Lyssikatos, Chief Scientific Officer, Insider Trading, Stock Sale, Form 4, 10b5-1 Plan, Equity Disposition